<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572012</url>
  </required_header>
  <id_info>
    <org_study_id>HALO-102-102</org_study_id>
    <nct_id>NCT01572012</nct_id>
  </id_info>
  <brief_title>Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers</brief_title>
  <official_title>Phase 1 Open-Label Randomized 4 Period Crossover Study Comparing Safety, Tolerability and PK of Ondansetron Given Subcutaneously With Hylenex Recombinant and Given Alone Intramuscularly, Intravenously and Orally in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halozyme Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label Phase 1 pharmacokinetic, tolerability, and safety study of&#xD;
      ondansetron and Hylenex given subcutaneously compared to ondansetron given intravenously,&#xD;
      intramuscularly, and orally in normal healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open label, 4 way crossover Phase 1 study of the pharmacokinetics,&#xD;
      safety and tolerability of a 4 mg dose of ondansetron administered subcutaneously with&#xD;
      Hylenex recombinant compared to 4 mg doses of ondansetron administered intravenously and&#xD;
      intramuscularly and an 8 mg dose of ondansetron administered orally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Overall Safety</measure>
    <time_frame>Days 1-31</time_frame>
    <description>Investigator assessment of infusion site observations for parenteral administration; Subject assessment of pain using the verbal response scale for parenteral administration; Subject assessment of pain using the visual analog scale for parenteral administration; Investigator assessment of systemic adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetics</measure>
    <time_frame>Days 1-5</time_frame>
    <description>Area of under the plasma concentration time curve (AUC); Time to achieve maximum plasma concentration (tmax); Maximum plasma concentration (Cmax); Plasma elimination half-life (t1/2); Relative bioavailability, ondansentron SC with Hylenex recombinant relative to ondansetron alone IV, IM, and PO</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Subcutaneous Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron + Hylenex administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron administered intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Ondansetron solution 4 mg single administration</description>
    <arm_group_label>Intramuscular Administration</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron + Hylenex</intervention_name>
    <description>Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration</description>
    <arm_group_label>Subcutaneous Administration</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zofran ODT</intervention_name>
    <description>Zofran ODT (8 mg) single administration</description>
    <arm_group_label>Oral Administration</arm_group_label>
    <other_name>ondansetron disintegrating tablet - oral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron solution</intervention_name>
    <description>Ondansetron solution (4 mg) single administration</description>
    <arm_group_label>Intravenous Administration</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female volunteers 19-65 years old&#xD;
&#xD;
          -  Females must be nonlactating and nonpregnant (negative serum pregnancy test at&#xD;
             screening)and agree to practice effective birth control for at least 30 days after&#xD;
             study completion&#xD;
&#xD;
          -  Nonsmoker or no tobacco/nicotine use in previous 6 months&#xD;
&#xD;
          -  Intact normal skin without obscuring tattoos, pigmentation or lesions&#xD;
&#xD;
          -  Adequate venous access in upper extremities&#xD;
&#xD;
          -  Normal vital signs, ECG, and labs or assessed by the Investigator as NCS&#xD;
&#xD;
          -  Serum hemoglobin within site's normal range&#xD;
&#xD;
          -  Negative drug and alcohol screen&#xD;
&#xD;
          -  Able to make decisions and comply with study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of drug or alcohol abuse or positive drug and alcohol screen&#xD;
&#xD;
          -  Abdominal surgery within the last 30 days&#xD;
&#xD;
          -  Phenylketonuria&#xD;
&#xD;
          -  Tobacco or nicotine use within previous 6 months&#xD;
&#xD;
          -  Hypersensitivity or contraindication to ondansetron or other 5-HT3 receptor agonists&#xD;
&#xD;
          -  Received ondansetron within 4 days prior to Day 1&#xD;
&#xD;
          -  Known allergy to hyaluronidase or other ingredient in Hylenex recombinant&#xD;
&#xD;
          -  Lower extremity edema&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 mL/min&#xD;
&#xD;
          -  Dehydration (Grade 2 or higher)&#xD;
&#xD;
          -  Hypersensitivity or contraindication to heparin&#xD;
&#xD;
          -  Abnormal ECG with clinically significant QT prolongation or history of&#xD;
&#xD;
          -  Female who is pregnant or breastfeeding&#xD;
&#xD;
          -  Participation in a clinical trial (drug or device) within 30 days of enrollment&#xD;
&#xD;
          -  Clinically significant medical history, major systemic disease, intercurrent illness,&#xD;
             physical examination finding, or clinical laboratory test result that risks the&#xD;
             subject's safety or interfere with interpretation of study results&#xD;
&#xD;
          -  Not able to comply with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel S Dychter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Halozyme Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icon Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>April 3, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2012</study_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>tolerability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

